Back to Top

AN EXPERIENCED GPCR DRUG DISCOVERY TEAM

Beacon Discovery was founded to take advantage of a unique collection of expertise in GPCR drug discovery.  We are comprised of a team of dedicated scientists who have worked together for more than a decade.  During the course of our careers, we have delivered in excess of 20 compounds into clinical testing.  We will maintain a focus on CNS research, whilst exploring innovative pathway-directed primary cell-based approaches to target other critical therapeutic areas with high unmet medical need.

WORKING AT THE FOREFRONT

The forefront of GPCR research has shifted in recent years from the constraints of traditional orthosteric receptor-ligand interactions towards an understanding of the importance of allosterism, biased ligands and persistent signaling.  In addition, the revolution in GPCR structural biology has resulted in significant advances in computational modeling of receptors.  We have a broad array of high throughput and targeted assay platforms addressing emerging GPCR biology, a well characterized diverse compound collection, state-of-the-art computational approaches, and a broad range of in vivo pharmacology expertise and capabilities. Our assets enable us to leverage these recent scientific advances and more efficiently drive drug discovery.

EXPERT GPCR RESEARCH TEAM


More than 50 GPCR Targets Evaluated

WORLD CLASS RESEARCH FACILITIES


Large screening library and HTS facilities

NOVEL APPROACHES TO TARGET AND LEAD ID


Simultaneously enabling targets and discovering lead molecules

A FOCUS ON THE CENTRAL NERVOUS SYSTEM


We know CNS drug discovery and development